Shire says Vyvanse provides improvements at 13 hours for children with ADHD

Shire says Vyvanse provides improvements at 13 hours for children with ADHD

Shire, the biopharmaceutical company based in Pennsylvania, US and Hampshire, UK, has announced the results of a study using Vyvanse to control symptoms of Attention Deficit Hyperactivity Disorder (ADHD).

The classroom trial involved children aged between six and 12 and it was found that the therapeutically inactive prodrug was effective from the 1.5-hour point to the last assessment at 13 hours.

After taking the oral stimulant, attention and behaviour were improved “significantly”, confirmed Dr Ann C Childress, study investigator.

She also said youngsters with ADHD needed something to control their symptoms not just throughout the school day but afterwards as well.

“This is encouraging news for physicians and patients seeking a long-acting ADHD treatment option as this study demonstrated symptom control during a 13-hour treatment day,” added Shire’s speciality pharmaceuticals president Mike Cola.

According to statistics published by the NHS, ADHD is believed to affect between three and nine per cent of young people and children of school age in the UK.

And in related news, recent research by the University of Buffalo in New York discovered that couples who have a child with ADHD are almost two times as likely to be get divorced by the time the youngster reaches eight years old than parents of those without the condition.